Refractory Hodgkin Lymphoma (DBCOND0029144)

Identifiers

Synonyms
Refractory Hodgkin's lymphoma / Hodgkin Disease Refractory / Hodgkin's disease refractory / Refractory Hodgkin Disease / Refractory Hodgkin's disease / Refractory Hodgkin lymphoma / Refractory Hodgkin lymphoma (disorder) / Hodgkin's disease NOS refractory

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Bendamustine
An antineoplastic nitrogen mustard agent used in the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed following rituximab therapy.
Carboplatin
A alkylating agent used to treat advanced ovarian cancer.
Carmustine
An alkylating agent used in the treatment of various malignancies, including brain tumours and multiple myeloma, among others.
Lomustine
An alkylating agent used as a part of chemotherapeutic regimens for the treatment of primary and metastatic brain tumors as well as refractory or relapsed Hodgkin's disease in addition to surgical and/or radiotherapeutic treatments.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT04268706
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)treatment2active_not_recruiting
NCT05352828
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapytreatment1active_not_recruiting
NCT01703949
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphomatreatment2recruiting
NCT03213665
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)treatment2active_not_recruiting
NCT04134325
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphomatreatment0active_not_recruiting
NCT03016871
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HLtreatment2active_not_recruiting
NCT04640779
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myelomatreatment1recruiting
NCT06484920
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLtreatment2recruiting
NCT03259503
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplanttreatment1active_not_recruiting
NCT01921387
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignanciestreatment1 / 2completed
NCT03013933
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphomatreatment1completed
NCT05595447
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphomatreatment2 / 3recruiting
NCT04681105
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignanciestreatment1active_not_recruiting
NCT04052997
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphomatreatment2completed
NCT01619761
NK Cells in Cord Blood Transplantationtreatment1unknown_status
NCT00860171
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaNo drug interventionstreatment1terminated
NCT02181478
Intra-Osseous Co-Transplant of UCB and hMSCtreatment0completed
NCT04871607
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphomatreatment2recruiting
NCT02456675
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphomatreatment2terminated
NCT02227199
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphomatreatment1 / 2active_not_recruiting
NCT00723099
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancertreatment2completed
NCT03432741
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancertreatment1suspended
NCT02304458
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomastreatment1 / 2completed
NCT03730363
Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphomatreatment1completed
NCT01701986
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphomatreatment1 / 2completed
NCT02254239
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphomatreatment1terminated
NCT04776265
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCTNo drug interventionsNot AvailableNot Availablerecruiting
NCT00789776
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancertreatment1 / 2completed
NCT02744612
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphomatreatment2active_not_recruiting
NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplanttreatment3completed
NCT03057795
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphomatreatment2active_not_recruiting
NCT00005803
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphomatreatment1 / 2completed
NCT05272384
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphomatreatment1recruiting
NCT02869633
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplanttreatment2completed
NCT00075478
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancertreatment3completed
NCT04938232
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLtreatment2active_not_recruiting
NCT03739606
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancertreatment2withdrawn
NCT03739619
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphomatreatment1 / 2active_not_recruiting
NCT01393717
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphomatreatment2completed
NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trialtreatment1terminated
NCT06487624
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumorstreatment1not_yet_recruiting
NCT05137886
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphomatreatment2recruiting
NCT02824029
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphomatreatment2active_not_recruiting
NCT01897012
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomastreatment1completed